HPV has become a well-developed model for understanding viral carcinogenesis, and the interdisciplinary work that ensued allowed for the development of the HPV vaccine. The vaccine is nearly universally effective, and leads to an overwhelming and seemingly durable antibody response. Still, there has been a relatively slow rate of HPV vaccine in the U.S. and globally. This translates to continuing susceptibility to the six HPV-related cancers that could be averted. In my research, I seek to fill in the blanks in the HPV story, with a focus on immune response, including a newly emerging area of innate immunity of HPV. I will present my research on HPV-related cancers in immune competent and immunosuppressed populations, immunogenetics, and a proposed trial to assess the impact of the prophylactic vaccine to prevent recurrence of high-grade lesions. The HPV story has not yet been fully told, and my work is motivated by prevention of HPV-related cancers among those who are unvaccinated.